Graciela S AlarcÃ³n

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/91357/publications.pdf

Version: 2024-02-01

180 papers 13,307 citations

47006 47 h-index 23533 111 g-index

185 all docs

185 docs citations

185 times ranked 10607 citing authors

#	Article	IF	CITATIONS
1	Association of Systemic Lupus International Collaborating Clinics Frailty Index With Damage in Systemic Lupus Erythematosus Patients: Results From a Multiethnic, Multicenter <scp>US</scp> Cohort of Patients With Lupus. Arthritis Care and Research, 2023, 75, 585-589.	3.4	5
2	Correspondence on †2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis' by Joanna C Robson <i>et al</i> alalalal Rheumatology classification criteria for microscopic polyangiitis'. Annals of the Rheumatic Diseases, 2023, 82, e197-e197.	0.9	1
3	Evaluating the Construct of Damage in Systemic Lupus Erythematosus. Arthritis Care and Research, 2023, 75, 998-1006.	3.4	7
4	Global Rheumatology Research: Frontiers, Challenges, and Opportunities. Arthritis and Rheumatology, 2022, 74, 1-4.	5.6	10
5	Metabolic syndrome predicts new damage in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort. Lupus, 2022, 31, 105-109.	1.6	5
6	ANCA-Associated Vasculitis in Latin America. Journal of Clinical Rheumatology, 2022, 28, 44-51.	0.9	11
7	Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort. Annals of the Rheumatic Diseases, 2022, 81, 370-378.	0.9	42
8	Characteristics associated with poor COVID-19 outcomes in individuals with systemic lupus erythematosus: data from the COVID-19 Global Rheumatology Alliance. Annals of the Rheumatic Diseases, 2022, 81, 970-978.	0.9	49
9	LLDAS (lupus low disease activity state) and/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: data from the Almenara Lupus Cohort. Lupus Science and Medicine, 2022, 9, e000616.	2.7	12
10	Longitudinal analysis of ANA in the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2022, 81, 1143-1150.	0.9	9
11	Severe flares are associated with a poorer health-related quality of life (HRQoL) in patients with SLE: data from the Almenara Lupus Cohort. Lupus Science and Medicine, 2022, 9, e000641.	2.7	7
12	Relationship between care model and disease activity states and health-related quality of life in systemic lupus erythematosus patients. Lupus, 2022, 31, 110-115.	1.6	2
13	B-Cell NHL Subtype Risk Associated with Autoimmune Conditions and PRS. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1103-1110.	2.5	4
14	Rising incidence and prevalence of systemic lupus erythematosus: a population-based study over four decades. Annals of the Rheumatic Diseases, 2022, 81, 1260-1266.	0.9	23
15	Cancer Risk in a Large Inception Systemic Lupus Erythematosus Cohort: Effects of Demographic Characteristics, Smoking, and Medications. Arthritis Care and Research, 2021, 73, 1789-1795.	3.4	13
16	Comparison of the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Systemic Lupus Erythematosus Classification Criteria With Two Sets of Earlier Systemic Lupus Erythematosus Classification Criteria. Arthritis Care and Research, 2021, 73, 1231-1235.	3.4	22
17	Applying the 2019 European Alliance of Associations for Rheumatology/American College of Rheumatology Lupus Criteria to Patients From the LUMINA Cohort: Results From the Multiethnic, Multicenter US Cohort. Arthritis Care and Research, 2021, 73, 1451-1455.	3.4	13
18	How well do the new classification criteria for SLE perform?. Nature Reviews Rheumatology, 2021, 17, 7-8.	8.0	3

#	Article	IF	Citations
19	Systemic lupus erythematosus: The search for the ideal biomarker. Lupus, 2021, 30, 181-203.	1.6	24
20	Understanding Risk Factors for Poor Outcomes in a Multiethnic Longitudinal Cohort. Rheumatic Disease Clinics of North America, 2021, 47, 55-64.	1.9	5
21	Communityâ€Engaged Research to Address Health Disparities in Systemic Lupus Erythematosus. Arthritis Care and Research, 2021, 73, 305-307.	3.4	3
22	A longitudinal multiethnic study of biomarkers in systemic lupus erythematosus: Launching the GLADEL 2.0 Study Group. Lupus, 2021, 30, 630-640.	1.6	2
23	Interest on the internet for systemic lupus erythematosus: Analysis of Google Trends in Latin American countries. Lupus, 2021, 30, 1342-1346.	1.6	2
24	Performance of the 2017 American College of Rheumatology/European League Against Rheumatism Provisional Classification Criteria for Antineutrophil Cytoplasmic Antibody–Associated Vasculitis in a Peruvian Tertiary Care Center. Journal of Clinical Rheumatology, 2021, Publish Ahead of Print, .	0.9	2
25	Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. Lupus, 2021, 30, 096120332110142.	1.6	3
26	Neuropsychiatric Events in Systemic Lupus Erythematosus: Predictors of Occurrence and Resolution in a Longitudinal Analysis of an International Inception Cohort. Arthritis and Rheumatology, 2021, 73, 2293-2302.	5.6	7
27	Organ damage in systemic lupus erythematosus. Revista Colombiana De ReumatologÃa, 2021, 28, 66-81.	0.1	2
28	Factors associated with neuropsychiatric involvement in Latin American patients with systemic lupus erythematosus. Lupus, 2021, 30, 096120332110203.	1.6	0
29	Predictors of hospitalization for COVID-19 in patients with autoimmune rheumatic diseases: results from a community cohort follow-up. Clinical Rheumatology, 2021, 40, 4725-4734.	2.2	8
30	Preconception, pregnancy, and lactation in systemic lupus erythematosus patients. Revista Colombiana De ReumatologÃa, 2021, 28, 156-156.	0.1	0
31	Correspondence on "New EULAR/ACR 2019 SLE classification criteria: defining ominosity in SLE―by Whittall Garcia et al. Annals of the Rheumatic Diseases, 2021, , annrheumdis-2021-220994.	0.9	1
32	Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review. Lupus Science and Medicine, 2021, 8, e000542.	2.7	24
33	1704 Identifying clusters of longitudinal autoantibody profiles associated with systemic lupus erythematosus disease outcomes. , 2021, , .		0
34	Health-Related Quality of Life and fatigue are associated with a higher work productivity impairment in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort. Lupus, 2021, 30, 2157-2161.	1.6	3
35	Impact of glucocorticoids on the incidence of lupus-related major organ damage: a systematic literature review and meta-regression analysis of longitudinal observational studies. Lupus Science and Medicine, 2021, 8, e000590.	2.7	31
36	Better Healthâ€Related Quality of Life in Systemic Lupus Erythematosus Predicted by Low Disease Activity State/Remission: Data From the Peruvian Almenara Lupus Cohort. Arthritis Care and Research, 2020, 72, 1159-1162.	3.4	20

#	Article	IF	Citations
37	Construction of a Frailty Index as a Novel Health Measure in Systemic Lupus Erythematosus. Journal of Rheumatology, 2020, 47, 72-81.	2.0	34
38	Peripheral Nervous System Disease in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2020, 72, 67-77.	5.6	39
39	Economic Evaluation of Damage Accrual in an International Systemic Lupus Erythematosus Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2020, 72, 1800-1808.	3.4	23
40	Prediction of Damage Accrual in Systemic Lupus Erythematosus Using the Systemic Lupus International Collaborating Clinics Frailty Index. Arthritis and Rheumatology, 2020, 72, 658-666.	5.6	26
41	Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus. Journal of Autoimmunity, 2020, 106, 102340.	6.5	27
42	Neuropsychiatric events in systemic lupus erythematosus: a longitudinal analysis of outcomes in an international inception cohort using a multistate model approach. Annals of the Rheumatic Diseases, 2020, 79, 356-362.	0.9	40
43	Clinical practice guidelines and recommendations for the management of patients with systemic lupus erythematosus: a critical comparison. Rheumatology, 2020, 59, e165-e168.	1.9	0
44	Age at diagnosis and health-related quality of life are associated with fatigue in systemic lupus erythematosus patients: Data from the Almenara Lupus Cohort. Lupus, 2020, 29, 1644-1649.	1.6	1
45	Measures of Fatigue in Patients With Rheumatic Diseases: A Critical Review. Arthritis Care and Research, 2020, 72, 369-409.	3.4	20
46	Prediction of hospitalizations in systemic lupus erythematosus using the Systemic Lupus International Collaborating Clinics Frailty Index (SLICCâ€FI). Arthritis Care and Research, 2020, , .	3.4	9
47	Accrual of Atherosclerotic Vascular Events in a Multicenter Inception Systemic Lupus Erythematosus Cohort. Arthritis and Rheumatology, 2020, 72, 1734-1740.	5.6	17
48	Clinical features, damage accrual, and survival in patients with familial systemic lupus erythematosus: data from a multi-ethnic, multinational Latin American lupus cohort. Lupus, 2020, 29, 1140-1145.	1.6	1
49	Serum uric acid is associated with damage in patients with systemic lupus erythematosus. Lupus Science and Medicine, 2020, 7, e000366.	2.7	6
50	Applying the 2019 EULAR/ACR lupus criteria to patients from an established cohort: a Latin American perspective. RMD Open, 2020, 6, e001097.	3.8	26
51	Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): data from the Peruvian Almenara Lupus Cohort. Lupus Science and Medicine, 2020, 7, e000419.	2.7	6
52	Antinuclear Antibody–Negative Systemic Lupus Erythematosus in an International Inception Cohort. Arthritis Care and Research, 2019, 71, 893-902.	3.4	70
53	Time in remission and low disease activity state (LDAS) are associated with a better quality of life in patients with systemic lupus erythematosus: results from LUMINA (LXXIX), a multiethnic, multicentre US cohort. RMD Open, 2019, 5, e000955.	3.8	17
54	Overrepresentation of Elderly Subjects in a Populationâ€Based Study of Antiphospholipid Syndrome: Comment on the Article by Duarteâ€GarcÃa et al. Arthritis and Rheumatology, 2019, 71, 1768-1769.	5.6	1

#	Article	IF	CITATIONS
55	Clinical predictors of remission and low disease activity in Latin American early rheumatoid arthritis: data from the GLADAR cohort. Clinical Rheumatology, 2019, 38, 2737-2746.	2.2	10
56	Predictors of Remission and Low Disease Activity State in Systemic Lupus Erythematosus: Data from a Multiethnic, Multinational Latin American Cohort. Journal of Rheumatology, 2019, 46, 1299-1308.	2.0	21
57	A Practical Roadmap for Writing of Medical Scientific Publications. Journal of Clinical Rheumatology, 2019, 25, 314-317.	0.9	0
58	Evaluating the Properties of a Frailty Index and Its Association With Mortality Risk Among Patients With Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1297-1307.	5.6	25
59	Use of combined hormonal contraceptives among women with systemic lupus erythematosus with and without medical contraindications to oestrogen. Rheumatology, 2019, 58, 1259-1267.	1.9	8
60	289â€Comparison of ACR 1982/1997 and EULAR/ACR classification criteria for systemic lupus erythematosus in two multiethnic cohorts. , 2019, , .		0
61	SAT0212â€ASSOCIATION BETWEEN SELF-EFFICACY AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		1
62	Jaccoud's arthropathy in SLE: findings from a Latin American multiethnic population. Lupus Science and Medicine, 2019, 6, e000343.	2.7	4
63	Medical Scientific Publications From Latin America. Journal of Clinical Rheumatology, 2019, 25, 157-158.	0.9	3
64	Low aspirin use and high prevalence of pre-eclampsia risk factors among pregnant women in a multinational SLE inception cohort. Annals of the Rheumatic Diseases, 2019, 78, 1010-1012.	0.9	12
65	Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2019, 71, 281-289.	5.6	55
66	Response to: â€~Clinical evidence guidelines in systemic lupus erythematosus: revaluation' by Scheinberg. Annals of the Rheumatic Diseases, 2019, 78, e120-e120.	0.9	1
67	Homocysteine levels are independently associated with damage accrual in systemic lupus erythematosus patients from a Latin-American cohort. Clinical Rheumatology, 2019, 38, 1139-1146.	2.2	3
68	Remission or low disease activity as a target in systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, e3-e3.	0.9	7
69	Rheumatoid arthritis in the indigenous qom population of Rosario, Argentina: aggressive and disabling disease with inadequate adherence to treatment in a community-based cohort study. Clinical Rheumatology, 2018, 37, 2323-2330.	2.2	9
70	A plausibly causal functional lupus-associated risk variant in the STAT1–STAT4 locus. Human Molecular Genetics, 2018, 27, 2392-2404.	2.9	34
71	Glucocorticoid use and factors associated with variability in this use in the Systemic Lupus International Collaborating Clinics Inception Cohort. Rheumatology, 2018, 57, 677-687.	1.9	37
72	Cerebrovascular Events in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis Care and Research, 2018, 70, 1478-1487.	3.4	55

#	Article	IF	Citations
73	Economic Evaluation of Lupus Nephritis in the Systemic Lupus International Collaborating Clinics Inception Cohort Using a Multistate Model Approach. Arthritis Care and Research, 2018, 70, 1294-1302.	3.4	21
74	Therapeutic Guidelines for Latin American Lupus Patients. Journal of Clinical Rheumatology, 2018, 24, 41-44.	0.9	7
75	CS-07â€Economic evaluation of damage accrual in an international SLE inception cohort. , 2018, , .		0
76	CS-23â€Remission and low disease activity state are associated with a better health-related quality of life in systemic lupus erythematosus in a primarily mestizo population. , 2018, , .		0
77	CS-13â€Remission and low disease activity state prevent hospitalizations and emergency room visits in systemic lupus erythematosus patients. , 2018, , .		0
78	Factors affecting quality of life in patients with systemic lupus erythematosus: important considerations and potential interventions. Expert Review of Clinical Immunology, 2018, 14, 915-931.	3.0	45
79	First Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, <i>Grupo Latino Americano de Estudio del) Tj ETQq1 Diseases, 2018, 77, 1549-1557.</i>	1 0.784314 rgt	3T _/ Overlock
80	Is Low Disease Activity Sufficient as a Target in Systemic Lupus Erythematosus? Comment on the Article by Petri et al. Arthritis and Rheumatology, 2018, 70, 2098-2099.	5.6	0
81	Genetic fine mapping of systemic lupus erythematosus MHC associations in Europeans and African Americans. Human Molecular Genetics, 2018, 27, 3813-3824.	2.9	43
82	Peripheral CD4+CD28null T-cells as predictors of damage inÂsystemic lupus erythematosus patients. Clinical and Experimental Rheumatology, 2018, 36, 1008-1013.	0.8	3
83	Serum uric acid levels contribute to new renal damage in systemic lupus erythematosus patients. Clinical Rheumatology, 2017, 36, 845-852.	2.2	19
84	Factors predictive of high disease activity early in the course of SLE in patients from a Latin-American cohort. Seminars in Arthritis and Rheumatism, 2017, 47, 199-203.	3.4	11
85	The evolving concept of SLE comorbidities. Expert Review of Clinical Immunology, 2017, 13, 753-768.	3.0	30
86	Epidemiology of systemic lupus erythematosus. Expert Review of Clinical Immunology, 2017, 13, 799-814.	3.0	167
87	Remission and Low Disease Activity Status (LDAS) protect lupus patients from damage occurrence: data from a multiethnic, multinational Latin American Lupus Cohort (GLADEL). Annals of the Rheumatic Diseases, 2017, 76, 2071-2074.	0.9	89
88	Transancestral mapping and genetic load in systemic lupus erythematosus. Nature Communications, 2017, 8, 16021.	12.8	314
89	X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and Sjögren's Syndrome. Arthritis and Rheumatology, 2016, 68, 1290-1300.	5.6	114
90	Disease features and outcomes in United States lupus patients of Hispanic origin and their Mestizo counterparts in Latin America: a commentary. Rheumatology, 2016, 55, kev280.	1.9	17

#	Article	IF	CITATIONS
91	Treat to target in systemic lupus erythematosus: a commentary. Clinical Rheumatology, 2016, 35, 1903-1907.	2.2	7
92	Systemic Lupus Erythematosus: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine, 2016, 34, 6572-6581.	3.8	4
93	Incomplete Systemic Lupus Erythematosus: Early Diagnosis or Overdiagnosis?. Arthritis Care and Research, 2016, 68, 285-287.	3.4	17
94	Decreased <i>SMG7</i> expression associates with lupus-risk variants and elevated antinuclear antibody production. Annals of the Rheumatic Diseases, 2016, 75, 2007-2013.	0.9	16
95	Abatacept for the treatment of systemic lupus erythematosus. Expert Opinion on Investigational Drugs, 2016, 25, 493-499.	4.1	33
96	Features associated with hematologic abnormalities and their impact in patients with systemic lupus erythematosus: Data from a multiethnic Latin American cohort. Seminars in Arthritis and Rheumatism, 2016, 45, 675-683.	3.4	43
97	Preferential association of a functional variant in complement receptor 2 with antibodies to double-stranded DNA. Annals of the Rheumatic Diseases, 2016, 75, 242-252.	0.9	10
98	The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology, 2016, 55, 252-262.	1.9	370
99	Circulating naive and memory CD4 ⁺ T cells and metabolic syndrome in patients with systemic lupus erythematosus: data from a primarily Mestizo population. Rheumatology, 2015, 54, 1302-1307.	1.9	16
100	Associations of Non-Hodgkin Lymphoma (NHL) Risk With Autoimmune Conditions According to Putative NHL Loci. American Journal of Epidemiology, 2015, 181, 406-421.	3.4	54
101	The number of flares patients experience impacts on damage accrual in systemic lupus erythematosus: data from a multiethnic Latin American cohort. Annals of the Rheumatic Diseases, 2015, 74, 1019-1023.	0.9	100
102	Lupus risk variants in the PXK locus alter B-cell receptor internalization. Frontiers in Genetics, 2015, 5, 450.	2.3	25
103	Lupus Risk Variant Increases pSTAT1 Binding and Decreases ETS1 Expression. American Journal of Human Genetics, 2015, 96, 731-739.	6.2	36
104	Mood Disorders in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study. Arthritis and Rheumatology, 2015, 67, 1837-1847.	5.6	98
105	Genetic associations of leptin-related polymorphisms with systemic lupus erythematosus. Clinical Immunology, 2015, 161, 157-162.	3.2	10
106	The IRF5â€"TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. Human Molecular Genetics, 2015, 24, 582-596.	2.9	74
107	Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort. Annals of the Rheumatic Diseases, 2015, 74, 1530-1536.	0.9	70
108	Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. Annals of the Rheumatic Diseases, 2015, 74, 1706-1713.	0.9	391

#	Article	IF	CITATIONS
109	The PANLAR Rheumatology Prize for Latin American Rheumatologists. Journal of Clinical Rheumatology, 2014, 20, 94-95.	0.9	2
110	Primary cardiac disease in systemic lupus erythematosus patients: protective and risk factors-data from a multi-ethnic Latin American cohort. Rheumatology, 2014, 53, 1431-1438.	1.9	33
111	Impact of Race and Ethnicity in the Course and Outcome of Systemic Lupus Erythematosus. Rheumatic Disease Clinics of North America, 2014, 40, 433-454.	1.9	58
112	Cancer risk in systemic lupus: An updated international multi-centre cohort study. Journal of Autoimmunity, 2013, 42, 130-135.	6.5	249
113	Headache in Systemic Lupus Erythematosus: Results From a Prospective, International Inception Cohort Study. Arthritis and Rheumatism, 2013, 65, 2887-2897.	6.7	84
114	Non-Lymphoma Hematological Malignancies in Systemic Lupus Erythematosus. Oncology, 2013, 85, 235-240.	1.9	30
115	Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000–2004. Arthritis and Rheumatism, 2013, 65, 753-763.	6.7	357
116	Erythropoiesis-stimulating Agent Use among Patients with Lupus Nephritis Approaching End-stage Renal Disease. Journal of Clinical & Cellular Immunology, 2013, 04, 179.	1.5	5
117	Analysis of autosomal genes reveals gene–sex interactions and higher total genetic risk in men with systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2012, 71, 694-699.	0.9	87
118	Anti-malarials exert a protective effect while Mestizo patients are at increased risk of developing SLE renal disease: data from a Latin-American cohort. Rheumatology, 2012, 51, 1293-1298.	1.9	46
119	Seizure disorders in systemic lupus erythematosus results from an international, prospective, inception cohort study. Annals of the Rheumatic Diseases, 2012, 71, 1502-1509.	0.9	143
120	Impact of genetic ancestry and sociodemographic status on the clinical expression of systemic lupus erythematosus in American Indian–European populations. Arthritis and Rheumatism, 2012, 64, 3687-3694.	6.7	70
121	Prevalence, incidence, and demographics of systemic lupus erythematosus and lupus nephritis from 2000 to 2004 among children in the US medicaid beneficiary population. Arthritis and Rheumatism, 2012, 64, 2669-2676.	6.7	163
122	Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis and Rheumatism, 2012, 64, 2677-2686.	6.7	3,838
123	Quality-of-Life Measurements in Multiethnic Patients with Systemic Lupus Erythematosus: Cross-Cultural Issues. Current Rheumatology Reports, 2010, 12, 237-249.	4.7	32
124	Antimalarial treatment may have a timeâ€dependent effect on lupus survival: Data from a multinational Latin American inception cohort. Arthritis and Rheumatism, 2010, 62, 855-862.	6.7	177
125	Factors predictive of thrombotic events in LUMINA, a multi-ethnic cohort of SLE patients (LXXII). Rheumatology, 2010, 49, 1720-1725.	1.9	27
126	Predictors of cardiovascular damage in patients with systemic lupus erythematosus: data from LUMINA (LXVIII), a multiethnic US cohort. Rheumatology, 2009, 48, 817-822.	1.9	99

#	Article	IF	Citations
127	Disease activity and damage are not associated with increased levels of fatigue in systemic lupus erythematosus patients from a multiethnic cohort: LXVII. Arthritis and Rheumatism, 2009, 61, 1179-1186.	6.7	71
128	Thrombosis in systemic lupus erythematosus: risk and protection. Expert Review of Cardiovascular Therapy, 2009, 7, 1541-1549.	1.5	30
129	Lessons from LUMINA: a multiethnic US cohort. Lupus, 2008, 17, 971-976.	1.6	23
130	Systemic Lupus Erythematosus in a Multiethnic US Cohort (LUMINA): LXI. Value of C-Reactive Protein as a Marker of Disease Activity and Damage. Journal of Rheumatology, 2008, 35, 2355-2358.	2.0	39
131	Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Annals of the Rheumatic Diseases, 2007, 66, 1168-1172.	0.9	428
132	African-American and Hispanic ethnicities, renal involvement and obesity predispose to hypertension in systemic lupus erythematosus: results from LUMINA, a multiethnic cohort (LUMINAXLV). Annals of the Rheumatic Diseases, 2007, 66, 618-622.	0.9	42
133	Damage, Accelerated Atherosclerosis, and Mortality in Patients With Systemic Lupus Erythematosus. Journal of Clinical Rheumatology, 2007, 13, 350-353.	0.9	13
134	Accelerated damage accrual among men with systemic lupus erythematosus: XLIV. Results from a multiethnic US cohort. Arthritis and Rheumatism, 2007, 56, 622-630.	6.7	147
135	A multiethnic, multicenter cohort of patients with systemic lupus erythematosus (SLE) as a model for the study of ethnic disparities in SLE. Arthritis and Rheumatism, 2007, 57, 576-584.	6.7	228
136	Using the Short Form 6D, as an overall measure of health, to predict damage accrual and mortality in patients with systemic lupus erythematosus: XLVII, results from a multiethnic US cohort. Arthritis and Rheumatism, 2007, 57, 986-992.	6.7	22
137	Poverty, not ethnicity, accounts for the differential mortality rates among lupus patients of various ethnic groups. Journal of the National Medical Association, 2007, 99, 1196-8.	0.8	40
138	Infections in Systemic Connective Tissue Diseases: Systemic Lupus Erythematosus, Scleroderma, and Polymyositis/Dermatomyositis. Infectious Disease Clinics of North America, 2006, 20, 849-875.	5.1	63
139	Systemic lupus erythematosus in a multiethnic US cohort: Clinical features, course, and outcome in patients with late-onset disease. Arthritis and Rheumatism, 2006, 54, 1580-1587.	6.7	115
140	Time to Renal Disease and End-Stage Renal Disease in PROFILE: A Multiethnic Lupus Cohort. PLoS Medicine, 2006, 3, e396.	8.4	90
141	Antimalarials in systemic lupus erythematosus: benefits beyond disease activity. Future Rheumatology, 2006, 1, 225-233.	0.2	8
142	Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual. Journal of Rheumatology, 2005, 32, 2150-5.	2.0	44
143	Systemic lupus erythematosus in three ethnic groups. XIV. Poverty, wealth, and their influence on disease activity. Arthritis and Rheumatism, 2004, 51, 73-77.	6.7	62
144	Systemic lupus erythematosus in a multiethnic lupus cohort (LUMINA). XVII. Predictors of self-reported health-related quality of life early in the disease course. Arthritis and Rheumatism, 2004, 51, 465-474.	6.7	141

#	Article	IF	CITATIONS
145	Systemic lupus erythematosus in three ethnic groups. XIX. Natural history of the accrual of the American College of Rheumatology criteria prior to the occurrence of criteria diagnosis. Arthritis and Rheumatism, 2004, 51, 609-615.	6.7	56
146	Systemic lupus erythematosus in a multiethnic US cohort (LUMINA): XXIII. Baseline predictors of vascular events. Arthritis and Rheumatism, 2004, 50, 3947-3957.	6.7	273
147	A 2-phase screening process for patients with Wegener's granulomatosis: a pilot study. Journal of Rheumatology, 2003, 30, 2420-1.	2.0	0
148	Systemic lupus erythematosus in three ethnic groups. VIII. Predictors of early mortality in the LUMINA cohort. Arthritis and Rheumatism, 2001, 45, 191-202.	6.7	299
149	Psychosocial and health status variables independently predict health care seeking in fibromyalgia. Arthritis and Rheumatism, 2001, 45, 362-371.	6.7	52
150	Systemic lupus erythematosus in three ethnic groups: IX. Differences in damage accrual. Arthritis and Rheumatism, 2001, 44, 2797-2806.	6.7	230
151	Pain complaints in patients with fibromyalgia versus chronic fatigue syndrome. Current Review of Pain, 2000, 4, 148-157.	0.7	29
152	Use of neuroimaging to understand abnormal pain sensitivity in fibromyalgia. Current Rheumatology Reports, 2000, 2, 141-148.	4.7	48
153	Abnormal Regional Cerebral Blood Flow in the Caudate Nucleus Among Fibromyalgia Patients and Non-Patients Is Associated with Insidious Symptom Onset. Journal of Musculoskeletal Pain, 1999, 7, 285-292.	0.3	26
154	Systemic lupus erythematosus in three ethnic groups: IV. Factors associated with self-reported functional outcome in a large cohort study. Arthritis and Rheumatism, 1999, 12, 256-266.	6.7	51
155	Systemic lupus erythematosus in three ethnic groups: V. Acculturation, health-related attitudes and behaviors, and disease activity in Hispanic patients from the LUMINA Cohort. Arthritis and Rheumatism, 1999, 12, 267-276.	6.7	29
156	Systemic lupus erythematosus in three ethnic groups: IV. Factors associated with selfâ€reported functional outcome in a large cohort study. Arthritis and Rheumatism, 1999, 12, 256-266.	6.7	1
157	Systemic lupus erythematosus in three ethnic groups: V. Acculturation, healthâ€related attitudes and behaviors, and disease activity in Hispanic patients from the LUMINA Cohort. Arthritis and Rheumatism, 1999, 12, 267-276.	6.7	2
158	Systemic lupus erythematosus in three ethnic groups: II. Features predictive of disease activity early in its course. Arthritis and Rheumatism, 1998, 41, 1173-1180.	6.7	202
159	Nutrient intake patterns, body mass index, and vitamin levels in patients with rheumatoid arthritis. Arthritis and Rheumatism, 1997, 10, 9-17.	6.7	37
160	Methotrexate in Rheumatoid Arthritis. BioDrugs, 1997, 8, 164-175.	4.6	9
161	Psychiatric diagnoses in patients with fibromyalgia are related to health care–seeking behavior rather than to illness. Arthritis and Rheumatism, 1996, 39, 436-445.	6.7	256
162	Health Care Seeking Behavior in Fibromyalgia:. Journal of Musculoskeletal Pain, 1994, 2, 79-87.	0.3	24

#	Article	IF	Citations
163	Issues in meta-analysis: An overview. Arthritis and Rheumatism, 1994, 7, 156-160.	6.7	5
164	Determinants of serious liver disease among patients receiving low-dose methotrexate for rheumatoid arthritis. Arthritis and Rheumatism, 1993, 36, 329-335.	6.7	187
165	Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee. Arthritis and Rheumatism, 1993, 36, 1196-1206.	6.7	239
166	Radiographic assessment of disease progression in rheumatoid arthritis patients enrolled in the cooperative systematic studies of the rheumatic diseases program randomized clinical trial of methotrexate, auranofin, or a combination of the two. Arthritis and Rheumatism, 1993, 36, 1364-1369.	6.7	48
167	Efficacy and safety of 10â€deazaaminopterin in the treatment of rheumatoid arthritis: A oneâ€year continuation, doubleâ€blind study. Arthritis and Rheumatism, 1992, 35, 1318-1321.	6.7	4
168	Comparison of auranofin, methotreaxate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial. Arthritis and Rheumatism, 1992, 35, 259-269.	6.7	139
169	Combination of disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis A survey of alabama rheumatologists. Arthritis and Rheumatism, 1991, 4, 48-51.	6.7	1
170	A comparison of the full and short versions of the arthritis impact measurement scales. Arthritis and Rheumatism, 1991, 4, 168-173.	6.7	17
171	Insufficiency fractures of the distal tibia misdiagnosed as cellulitis in three patients with rheumatoid arthritis. Arthritis and Rheumatism, 1991, 34, 912-915.	6.7	24
172	Prognosis in systemic lupus erythematosus. Arthritis and Rheumatism, 1990, 33, 37-48.	6.7	323
173	Molecular forms of IgA rheumatoid factor in serum and synovial fluid of patients with rheumatoid arthritis. Arthritis and Rheumatism, 1986, 29, 1194-1202.	6.7	28
174	Double-blind, multicenter controlled trial comparing topical dimethyl sulfoxide and normal saline for treatment of hand ulcers in patients with systemic sclerosis. Arthritis and Rheumatism, 1985, 28, 308-314.	6.7	42
175	Pure red cell aplasia and protein-losing enteropathy in a patient with systemic lupus erythematosus. Arthritis and Rheumatism, 1985, 28, 1059-1061.	6.7	31
176	Familial studies in human brucellosis. Tissue Antigens, 1985, 26, 77-79.	1.0	7
177	DR antigens in systemic sclerosis: lack of clinical correlations. Tissue Antigens, 1985, 26, 156-158.	1.0	20
178	Azathioprine versus d-penicillamine in rheumatoid arthritis patients who have been treated unsuccessfully with gold. Arthritis and Rheumatism, 1984, 27, 721-727.	6.7	57
179	Differential patterns of in vitro IgM rheumatoid factor synthesis in seronegative and seropositive rheumatoid arthritis. Arthritis and Rheumatism, 1982, 25, 150-155.	6.7	21
180	Characteristics associated with Covid-19 in patients with Rheumatic Disease in Latin America: data from the Covid-19 Global Rheumatology Alliance physician-reported registry. Global Rheumatology, 0,	0.0	10